MediWound Q3 net loss more than doubles to $5.99 million; revenue falls 34% to $3.57 million
MDWD•MediWound reported a third-quarter 2026 net loss of $5.99 million, more than double a year earlier, as revenue fell 34% to $3.57 million. A November offering raised $17.25 million in gross proceeds; its 2026 revenue outlook remains uncertain pending U.S. government funding discussions.
1. Quarterly results and outlook
MediWound's third-quarter net loss more than doubled year over year to $5.99 million, reflecting lower non-cash warrant revaluation income, while revenue fell 34% to $3.57 million, primarily due to lower U.S. government-related development services revenue. A November public offering raised $17.25 million in gross proceeds; the EscharEx Phase III VALUE trial remains on track for interim assessment and enrollment completion by the end of first-quarter 2027, while the 2026 revenue outlook remains uncertain pending funding discussions for a planned U.S. manufacturing facility.
